Apyx Medical Corp. (NASDAQ: APYX) reported Q2 EPS of ($0.12), $0.03 better than the analyst estimate of ($0.15). Revenue for the quarter came in at $11.2 million versus the consensus estimate of $8.86 million.

We are pleased to deliver exceptional growth in sales of our Advanced Energy products which exceeded our expectations for the second quarter, reflecting solid execution by our team and continued improvement in the broader operating environment,” said Charlie Goodwin, President and Chief Executive Officer. “Most notably, we saw impressive growth in global sales of our Advanced Energy handpieces, which increased by over 270% year-over-year, driven by utilization-based demand both domestically and internationally. We were also pleased to see important contributions from global sales of our generators, which increased by more than 210% year-over-year, reflecting strong adoption of our technology in the U.S. and key international markets as the capital equipment environment continued to recover.”

Mr. Goodwin continued: “We are increasing our 2021 revenue outlook today to reflect both our stronger-than-expected sales performance during the second quarter, as well as our improved expectations for the second half of the year. While the pace and timing of recovery in the global capital equipment environment remains uncertain, we expect to see continued improvement coupled with strong utilization trends as we move through the balance of the year. We look forward to building on our recent momentum by continuing to raise awareness of our innovative Helium Plasma Technology and its potential benefits for surgeons and patients around the world.”

For earnings history and earnings-related data on Apyx Medical Corp. (APYX) click here.